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Abstract
To prevent endometrial carcinoma in Lynch syndrome (LS), regular gynecological surveillance visits and prophylactic surgery 
are recommended. Previous data have shown that prophylactic hysterectomy is an effective means of cancer prevention, while 
the advantages and disadvantages of surveillance are somewhat unclear. We aimed to evaluate female LS carriers’ attitudes 
towards regular gynecological surveillance and factors influencing their decision-making on prophylactic surgery that have 
not been well documented. Pain experienced during endometrial biopsies was also evaluated. Postal questionnaires were sent 
to LS carriers undergoing regular gynecological surveillance. Questionnaires were sent to 112 women with LS, of whom 
76 responded (68%). Forty-two (55%) had undergone prophylactic hysterectomy by the time of the study. The majority of 
responders (64/76; 84.2%) considered surveillance appointments beneficial. Pain level during endometrial biopsy was not 
associated with the decision to undergo prophylactic surgery. The level of satisfaction the women had with the information 
and advice provided during surveillance was significantly associated with the history of prophylactic hysterectomy (satisfac-
tion rate of 73.2% versus 31.8% of nonoperated women, p = 0.003). The women who had undergone prophylactic surgery 
were older than the nonoperated women both at mutation testing (median of 42.3 years versus 31.6 years, p < 0.001) and at 
the time of the study (median of 56.9 years versus 46.0 years, respectively, p < 0.001). Women with LS pathogenic variants 
have positive experiences with gynecological surveillance visits, and their perception of the quality of the information and 
advice obtained plays an important role in their decision-making concerning prophylactic surgery.
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Introduction
Lynch syndrome (LS), previously called hereditary nonpoly-
posis colorectal cancer (HNPCC), is a cancer predisposition 
syndrome with a dominant inheritance caused by pathogenic 
(path_) germline variants in the DNA mismatch repair 
(MMR) genes MLH1, MSH2, MSH6, and PMS2 [1]. In addi-
tion to the early occurrence of colorectal cancer (CRC), LS 
is also characterized by certain extracolonic cancers (ECCs), 
of which endometrial carcinoma (EC) is the most common 
[1]. Carriers of different path_MMR variants exhibit distinct 
patterns of cancer risk and survival. The cumulative inci-
dence of EC for path_MLH1, path_MSH2, path_MSH6 and 
path_PMS2 is 42.7%, 56.7%, 46.2% and 26.4% at the age of 
75 years, respectively [2].
ECs associated with path_MMR variants usually occur at 
younger ages than in the general population. The average age 
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at EC diagnosis in women with LS in a recent retrospective 
series was reported to be 47–49 years (range 26–87) [1, 3]. 
The steepest increase in the cumulative incidence of EC was 
between 50 and 60 years of age in the Prospective Lynch 
Syndrome Database (PLSD) [2].
The clinical practice and guidelines for gynecological 
surveillance and prophylactic surgery for female LS variant 
carriers vary in different countries [4]. Common practice 
in countries performing surveillance in Europe, Australia, 
North America and South America is either annual on bian-
nual gynecological examination [5]. Based on current pub-
lished studies, there are no adequate data for evidence-based 
clinical decisions based on findings during surveillance [6]. 
In Finland, after predictive genetic testing was nationally 
introduced in 1995, annual gynecological examinations 
have become common clinical practice, including pelvic 
ultrasound examination and endometrial biopsy, starting at 
approximately 35 years of age [7]. Prophylactic surgery, or 
hysterectomy with or without bilateral salpingo-oophorec-
tomy or salpingectomy, has usually been performed after 
the age of 40 years, when having children is complete, or at 
the age of menopause, depending on the mutation carrier’s 
preference [3, 4]. However, some pathogenic variant carri-
ers disagree with the surgery recommendation and refuse to 
undergo prophylactic hysterectomy. The cancer-preventing 
effects of prophylactic surgery have been proven by clinical 
trials [6]. A few previous studies have evaluated the process 
of decision-making on prophylactic surgery, the effects of 
gynecological surveillance and prophylactic hysterectomy 
on the quality of life, and the pain associated with endome-
trial sampling of the mutation carriers [4, 8–10].
Since data on the attitudes of LS mutation carriers 
towards prophylactic surgery and gynecological surveil-
lance are limited and even absent in Finland, we wanted 
to evaluate the decision-making process, satisfaction with 
surveillance, and pain associated with endometrial biopsies 
in this questionnaire-based study.
Materials and methods
Study subjects
The present retrospective cohort study was performed at 
Tampere University Hospital (TAUH), Tampere, Finland. 
Informed consent was obtained from all study participants, 
and the study protocol was approved by the TAUH Ethical 
Committee (decision code ETL R10079, dated 4.1.2011).
The study cohort included Finnish women with inher-
ited pathogenic MMR gene variants identified from the 
nationwide Finnish LS Registry (LSRFi), [11] which has 
been described in more detail previously [12, 13, 14, 15]. 
Briefly, the LSRFi includes 300 families and approximately 
1400 verified germline MMR variant carriers (http://www.
hnpcc .fi/). Healthy women belonging to a Finnish LS family 
receive counseling from clinical geneticists and gynecolo-
gists. After counseling, the decision to undergo mutation 
testing and its timing are based on the woman’s individual 
choice. Regular follow-up of the mutation-positive women 
starts after the mutation testing. Prophylactic hysterectomy 
is generally recommended for all female mutation carriers 
after 35–40 years of age, when the mutation carrier is no 
longer wishing for a pregnancy. Surgery is recommended by 
the age of menopause at the latest. If prophylactic surgery 
has not been performed by the age of 40, annual follow-up 
visits are recommended. The removal of the ovaries is dis-
cussed with mutation carriers and is usually performed if the 
woman is peri- or postmenopausal or if she, after receiving 
information, decides to have them removed before meno-
pause. Finally, salpingo-oophorectomy is recommended at 
the time of menopause at the latest.
One hundred and twelve female LS carriers at least 30 
years of age, with no history of endometrial or ovarian 
cancer and having previously consented regarding registry 
inquiries, were identified from the LSRFi. The study cohort 
is described in Table 1. A postal questionnaire was sent to 
these 112 women and was re-sent to those who did not return 
questionnaires within 6 months of the first mailing.
Questionnaires
Study participants completed a retrospective questionnaire 
collecting data on their history of other types of cancer, 
Table 1  Characteristics of the LS cohort (112 Finnish females with a 
path_MMR variant)
LS Lynch syndrome, path_MMR pathogenic variant of DNA mis-
match repair gene
Whole 
LS cohort 
(N = 112)
Study popula-
tion (responders) 
(N = 76)
Age
 Median (range) 49 (30–89) 52 (30–82)
Age at mutation testing
 Median 38 (20–72) 36 (22–65)
Distribution of MMR genes
 MLH1 72 (64%) 47 (62%)
 MSH2 32 (29%) 22 (29%)
 MSH6 8 (7%) 7 (9%)
History of other cancer (Y/N)
 Y 42 (38%) 24 (33%)
 N 70 (62%) 49 (67%)
Prophylactic surgery performed
 Y 63 (56%) 42 (68%)
 N 49 (44%) 24 (32%)
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family history, parity, and age at mutation testing and pro-
phylactic gynecological surgery, if performed. Data on the 
subjects’ attitudes towards gynecological surveillance and 
prophylactic surgery and their experiences with these proce-
dures were also collected. Pain associated with endometrial 
biopsies was evaluated with a numeric rating scale (NRS; 
0–10, 0 = no pain and 10 = worst imaginable pain). Subjects 
who stated they could not recall or evaluate the pain level 
did not answer this question. A detailed description of the 
questionnaire content is presented in Table 2.
Statistical analysis
IBM SPSS statistics software, version 22 (IBM SPSS, Inc., 
Armonk, NY, USA), was used for the statistical analyses. 
The association of categorized variables with prophylactic 
surgery decisions was performed using the chi-squared test. 
Two-tailed P < 0.05 values were considered to indicate sta-
tistically significant differences. The association of continu-
ous variables (e.g., NRS and number of deliveries) with the 
history of prophylactic surgery was carried out using the t 
test or a nonparametric test when appropriate. NRS scores 
and the number of deliveries were also categorized (NRS 
0 to 5 versus 6 or more and parity of 0 versus 1 or more 
deliveries) in the statistical analyses. When assessing factors 
possibly influencing prophylactic surgery decision-making, 
patients who had a hysterectomy for nonprophylactic reasons 
were excluded from the analyses.
Results
Seventy-six women returned the questionnaire, resulting in a 
68% response rate. The distribution of the affected genes was 
as follows: 62% MLH1, 29% MSH2 and 9% MSH6 muta-
tions. A prophylactic hysterectomy was performed on 42 
subjects of this population (55%) at the median age of 42.0 
years (range 32.0–67.0). Twenty-four subjects had not had 
a hysterectomy at the time of the survey, and 10 subjects 
had a nonprophylactic hysterectomy performed for benign 
medical reasons, such as uterine myomas, menorrhagia with-
out endometrial hyperplasia, and pelvic floor prolapses, for 
which they were excluded from the analyses concerning 
prophylactic hysterectomy. The characteristics of the study 
cohort (both responders and nonresponders) are summarized 
in Table 1.
Among subjects not having had a hysterectomy per-
formed at the time of the study, eight (33.3%) reported they 
Table 2  Details of the questionnaire used
Feature Further information Measurement/response
Time of predictive testing Date/year
Age at predictive testing Number
Relationship status before testing In a relationship? Y/N
Relationship status on study In a relationship? Y/N
Prophylactic surgery performed Y/N
Has attended follow-up appointments Y/N
Considers follow-up beneficial If “yes” to previous Y/N
Parity Number of deliveries Number
Experienced pain in endometrial biopsy NRS 0–10 Number
Satisfied with the advice provided by the professionals In general Y/N
Enough information provided on possible adverse effects of prophy-
lactic surgery
Gynecological prolapses Y/N
Urinating complaints Y/N
G-I tract complaints Y/N
Has felt pressure for prophylactic surgery Y/N
Satisfied with decision to have surgery If performed Y/N
Planning to have prophylactic surgery If not performed Y/N
Cancer other than gynecological cancer in family Personal history or family member Y/N
Which cancer Description
Family member died of gynecological cancer Y/N
Experience of personal state of health Poor/intermediate/good 0/1/2
Poor tolerance of insecurity Own experience Y/N
Strong fear of cancer Y/N
Strong fear of surgery/operations Y/N
Experience of surgery as responsibility Y/N
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were not planning to have a prophylactic hysterectomy at all, 
and 16 (66.7%) reported not having decided yet about the 
surgery or did not respond.
The median age at mutation testing among subjects with a 
prophylactic hysterectomy performed was 42.3 years (range 
25–65), compared to 31.6 years (range 22–48) for subjects 
with no hysterectomy performed (p < 0.001). At the time 
of the study, the median age of subjects with a prophylac-
tic hysterectomy performed was 56.9 years (range 43–72), 
compared to 43.2 years (range 30–76) for subjects with no 
hysterectomy performed (p < 0.001).
The median time interval between mutation testing and 
the study survey was 11 years (range 6–29 years) among the 
study subjects still in surveillance (not having undergone 
prophylactic surgery). The median duration of surveillance 
(median time interval between mutation testing and prophy-
lactic surgery) was 6 years (0–14 years), and the median 
time interval between surgery and the study questionnaire 
was 9 years (1–38 years) among the prophylactically oper-
ated subjects.
Sixty-eight (89.5%) of the responders reported attending 
regular surveillance appointments that were provided. Six 
subjects reported not having been offered appointments at 
all, and two subjects did not respond to this question. Sixty-
four (84.2%) of the subjects considered appointments to be 
beneficial, 10 subjects did not respond to this question and 
only two patients considered appointments unbeneficial.
Pain associated with endometrial sampling measured by 
NRS, overall satisfaction with the given information and 
all the background factors possibly having an influence on 
women’s attitudes and decisions on prophylactic surgery 
obtained from the questionnaires are summarized in Table 3. 
Fifty-four subjects evaluated pain associated with endome-
trial biopsy, while 22 (29%) of the subjects did not respond 
Table 3  Background characteristics and factors collected from questionnaires obtained from prophylactically operated vs. nonoperated mutation 
carriers
a Defined by study questionnaire responders
b 10 subjects with nonprophylactic hysterectomy excluded from comparison
c Comparison between nonoperated and prophylactically operated subjects
d Total of 54 subjects answered this question (22 subjects did not respond)
Reported variables Study population 
(N = 76)a
Prophylactic hysterectomy 
performed (N = 42)b
Nonoperated (N = 24) p  valuec
n (%) n (%) n(%)
1. Parity: 1 or more deliveries 66 (86.8) 37 (88.1) 21 (87.5) 1.000
2. Own health considered intermediate or good 50 (65.8) 24 (58.5) 18 (75.0) 0.282
3. In a relationship at mutation diagnosis 67 (88.2) 40 (95.2) 19 (79.2) 0.089
4. Attended gynecological appointments regularly 68 (89.5) 37 (88.1) 21 (87.5) 1.000
5. Cancer other than gynecological cancer in family 73 (96.0) 39 (92.9) 24 (100.0) 0.295
6. Family member died of gynecological cancer 17 (22.3) 12 (29.3) 4 (16.7) 0.373
7. Poor tolerance of feeling of insecurity 13 (17.1) 5 (11.9) 5 (20.8) 0.477
8. Strong fear of cancer 32 (42.1) 19 (45.2) 10 (41.7) 0.803
9. Strong fear of surgery/operations 12 (15.7) 6 (14.3) 4 (16.7) 1.000
10. Experience of surgery as responsibility 16 (21.0) 12 (29.3) 3 (12.5) 0.142
11. Feels/has felt pressure for surgery 20 (26.3) 14 (35.9) 5 (22.7) 0.391
12. Satisfied with information and advice in general 43 (56.6) 30 (73.2) 7 (31.8) 0.003
13. Satisfied with information on possible postoperative 
disadvantages
a. Urinary complaints 18 (23.6) 11 (28.9) 2 (9.1) 0.106
b. Chronic pelvic pain 20 (26.3) 12 (31.6) 3 (13.6) 0.215
c. GI-tract complaints 19 (25.0) 12 (31.6) 2 (9.1) 0.061
d. Pelvic prolapses 19 (25.0) 12 (31.6) 2 (9.1) 0.061
14. Endometrial biopsy pain (NRS score) (N = 54)d (N = 28)d (N = 19)d
a. 0–5 39 (72.2) 21 (75.0) 11 (57.9)
b. 6–10 15 (27.8) 7 (25.0) 8 (42.1) 0.339
15. Median age, years Year (range) Year (range) Year (range)
a. At mutation testing 35.2 (22–65) 42.3 (25–65) 31.6 (22–48) < 0.001
b. At survey 48.8 (30–76) 56.9 (43–72) 43.2 (30–76) < 0.001
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to this question. The median NRS among Women with LS 
was 3.5. Most women (72.2%) reported mild or intermedi-
ate pain associated with endometrial biopsy measured by 
NRS (NRS 0–5), and strong pain (NRS 6–10) was reported 
by 27.8% of women. Approximately 40% of participants 
reported pain to be very mild or there was no pain at all 
(NRS 0 to 2). Pain levels during endometrial biopsy did 
not influence the rate of prophylactic surgeries when ana-
lyzed either as a continuous variable or when categorized. 
Regardless of the history of prophylactic hysterectomy, a 
majority of women (43/76; 59.7%) reported satisfaction 
with the information and advice regarding LS in general and 
prophylactic surgery provided by gynecologists. Only four 
subjects did not answer this question. The self-reported sat-
isfaction with general LS-associated information and advice 
by experts was dependent on the history of prophylactic 
hysterectomy: 73.2% of the operated patients were satisfied 
versus only 31.8% of the nonoperated patients (p = 0.003; 
Table 3). The compliance rate with gynecological surveil-
lance was similar among operated and nonoperated women 
(88.1% versus 87.5%, respectively, p = 1.00; Table 3).
In addition, there was a trend for women who chose pro-
phylactic hysterectomy to have received more information 
on certain postoperative complications than women who had 
not chosen surgery yet (p = 0.061 for information on GI-tract 
postoperative complications and pelvic prolapses; Table 3).
Discussion
In this study, LS pathogenic variant carriers’ attitudes 
towards gynecological surveillance and satisfaction with 
the advice and information provided by experts were sig-
nificantly associated with having had prophylactic surgery. 
To our knowledge, this finding highlights the importance of 
general information in this context and emphasizes the role 
of attending medical staff. On the other hand, compliance 
with surveillance was similar between prophylactically oper-
ated and nonoperated women, suggesting that the quality of 
information may play a significant role in decision-making.
Parity and experienced pain during endometrial sampling 
did not correlate with the decision to undergo prophylactic 
surgery. A previous study indicated that parity influences 
decision-making, but the data were derived from a very 
small study population of ten women with LS [8]. Severe 
pain experienced during endometrial sampling has been pre-
viously shown to be the main reason to quit screening, thus 
possibly lowering the threshold for surgery [10]. Different 
populations may explain differences in the results concern-
ing the experience of pain during endometrial sampling. 
Since ultrasound examination is not sufficient as a single 
surveillance method in terms of EC prevention, [16] it is a 
relief that pain associated with endometrial sampling was 
not a significant factor for decision-making, at least in our 
study population. The association of older age at mutation 
testing and at survey was expected since all recommenda-
tions for the initiation of surveillance and the timing of pro-
phylactic surgery are age-dependent.
The majority of subjects considered gynecological sur-
veillance to be beneficial in general. There have been some 
previous qualitative studies on the topic showing experi-
enced benefit [8, 10]. We show that some of the study 
subjects reported being either inadequately or not at all 
informed about the risks and possible long-term side effects 
of prophylactic surgery. Earlier qualitative studies evaluat-
ing surgery decisions have reported similar results: muta-
tion carriers are mainly satisfied with prophylactic surgery 
decisions, but nonoperated women are not completely satis-
fied with the information they receive [6, 8]. One possible 
explanation for this is that more detailed surgery-related 
information is provided only when the decision to undergo 
surgery has been made. From this retrospective analysis, it 
is not possible to draw straightforward conclusions, but it is 
probable that women with LS may warrant more detailed 
and structured information on surgery during surveillance.
Some of our study subjects were not satisfied with the 
surveillance protocol. A few LS carriers reported not being 
informed at all about gynecological surveillance appoint-
ments. This probably influenced their decision-making on 
prophylactic surgery and may have led them to refuse it, thus 
keeping them susceptible to EC. This finding emphasizes the 
importance of structured national guidelines for the manage-
ment of LS.
The strengths of our study include a well-defined popula-
tion of women with LS who were all verified as germline 
pathogenic variant carriers and were not just women who 
had a strong family history of EC or CRC. The study cohort 
identified from the LSRFi included 112 women, and the 
response rate was quite high (68%), which is in line with 
previous questionnaire-based studies among subjects with 
a hereditary cancer predisposition [14, 15].
There are some limitations to our study. The setting is ret-
rospective, and a questionnaire survey is subject to the risk 
of misremembering background factors. This misremember-
ing may therefore cause recall bias. However, we consider 
that a questionnaire-based survey is also a valuable method 
to collect the points of view and experiences of women with 
LS. Prophylactically operated subjects were expectedly sig-
nificantly older at the time of mutation diagnosis and at 
study than nonoperated women, which can also cause some 
bias. A comparison of responders to nonresponders did not 
reveal any major concerns other than the slightly more fre-
quent rate of prophylactic hysterectomy among the respond-
ers, which may cause potential bias and must be taken into 
account when interpreting the present results. Some of 
the study subjects had a hysterectomy for nonprophylactic 
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reasons, and they had to be excluded from the analyses when 
estimating the factors influencing the decision-making about 
prophylactic surgery.
In conclusion, we show here new descriptive data on the 
attitudes towards surveillance and factors associated with the 
history of prophylactic surgery in a Finnish cohort of women 
with LS. Based on our results, surveillance is well accepted. 
Considering the results of our study, we suggest that the 
mutation carriers should be systematically informed about 
surveillance and its aims and about prophylactic surgery. We 
suggest that information should be offered regardless of the 
timing of the prophylactic surgery.
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